Controlled-release oxycodone tablets after transdermal-based opioid therapy in patients with cancer and non-cancer pain

被引:3
|
作者
Ravera, Enrico [1 ]
Di Santo, Salvatore [1 ]
Bosco, Rosa [1 ]
Arboscello, Claudio [2 ]
Chiarlone, Renato [2 ]
机构
[1] Osped Bra, Azienda Sanitaria Locale Alba Bra Cn CN2, Savona, Italy
[2] Osped San Paolo, ASL Savonese 2, Savona, Italy
关键词
Chronic pain; oxycodone CR; quality of life; transdermal opioids; AROUND-THE-CLOCK; DOUBLE-BLIND; PHARMACOLOGICAL-TREATMENT; MORPHINE; EFFICACY; MANAGEMENT; SAFETY; HYDROMORPHONE; MODEL;
D O I
10.1007/BF03325231
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Background and aims: Several publications and guidelines stress the efficacy and safety of opioid-based therapy for cancer and non-cancer pain management. The first point of the World Health Organization (WHO) guidelines recommends that, if possible, analgesics should be given by mouth. This advice fully matches the European Society for Medical Oncology (ESMO) guidelines, which advise that opioids should be titrated to take effect as rapidly as possible. The European Association for Palliative Care (EAPC) guidelines specify that transdermal fentanyl should be administered only in patients with stable analgesic requirements. The aim of this study was to assess the efficacy and influence on the quality of life of controlled-release (CR) oxycodone in patients who had obtained no or only partial pain relief after transdermal (TTD)-based opioid therapy. Methods: Forty-one consecutive patients experiencing persistent cancer and non-cancer related pain and in treatment with transdermal-based opioid therapy for at least 5 days were enrolled in this open-label, multicenter observational study. All patients were switched from transdermal to oral opioid therapy with oxycodone CR for 21 days. Pain intensity was rated on a numeric rating scale (NRS) from 0 to 10 (0=no pain, 10=maximum severity). Patients were asked to rate their perceptions on efficacy and pain interference on the quality of life on an NRS from 0 to 10 (0=no interference, 10=maximum interference). Results: After 3 days with oxycodone CR, pain intensity decreased by 38.83% (p<0.001) and maintained a significant decrease throughout the period (T0-T7: -59.71%, p<0.001; T0-T21: -65.75%, p<0.001). The average daily dose of oxycodone CR increased from 68.75 mg at baseline to 72.39 mg after 7 days and was maintained stable until the study ended. At T0, 56.10% of patients suffered from severe pain (NRS 7-10); this percentage had decreased to 2.56% at the end of the study. About 7% of patients considered transdermal therapy effective at baseline; after 21 days, 72.22% and 19.44% of patients considered it effective and very effective, respectively. Quality of life improved significantly during the 21 days with the oral treatment (p<0.001). Conclusions: Switching from transdermal opioid to oxycodone CR treatment is effective and leads to patients' improved satisfaction and quality of life. (Aging Clin Exp Res 2011; 23: 328-332) (C)2011, Editrice Kurtis
引用
收藏
页码:328 / 332
页数:5
相关论文
共 50 条
  • [41] Effect of chronic opioid therapy on actual driving performance in non-cancer pain patients
    Schumacher, Markus B.
    Jongen, Stefan
    Knoche, Anja
    Petzke, Frank
    Vuurman, Eric F.
    Vollrath, Mark
    Ramaekers, Johannes G.
    PSYCHOPHARMACOLOGY, 2017, 234 (06) : 989 - 999
  • [42] DIFFERENTIAL PATTERNS OF PERSISTENT OPIOID USE IN PATIENTS WITH CANCER AND NON-CANCER PAIN
    Sani, A. R.
    Zin, C. S.
    Noor, Z. M.
    Mohamed, A. H.
    Nissen, L. M.
    VALUE IN HEALTH, 2016, 19 (07) : A814 - A814
  • [43] Problems and concerns of patients receiving chronic opioid therapy for chronic non-cancer pain
    Sullivan, Mark D.
    Von Korff, Michael
    Banta-Green, Caleb
    Merrill, Joseph O.
    Saunders, Kathleen
    PAIN, 2010, 149 (02) : 345 - 353
  • [44] Treatment of persistent pain associated with osteoarthritis with controlled-release oxycodone tablets in a randomized controlled clinical trial
    Markenson, JA
    Croft, J
    Zhang, PG
    Richards, P
    CLINICAL JOURNAL OF PAIN, 2005, 21 (06): : 524 - 535
  • [45] Efficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients with cancer and chronic non-cancer pain
    Clark, AJ
    Ahmedzai, SH
    Allan, LG
    Camacho, F
    Horbay, GLA
    Richarz, U
    Simpson, K
    CURRENT MEDICAL RESEARCH AND OPINION, 2004, 20 (09) : 1419 - 1428
  • [46] Clinical Equivalence of Controlled-Release Oxycodone 20 mg and Controlled-Release Tramadol 200 mg after Surgery for Breast Cancer
    Kampe, Sandra
    Wolter, Karsten
    Warm, Mathias
    Dagtekin, Oguzhan
    Shaheen, Sasan
    Landwehr, Susanne
    PHARMACOLOGY, 2009, 84 (05) : 276 - 281
  • [47] SURVIVAL ON CONTROLLED-RELEASE MORPHINE VERSUS CONTROLLED-RELEASE OXYCODONE IN OPIOID-NAIVE PATIENTS WITH NON-MALIGNANT PAIN: DATA FROM DANISH NATIONAL HEALTH REGISTERS
    Christensen, R.
    Bliddal, H.
    Tarp, S.
    Henriksen, M.
    Vestergaard, P.
    OSTEOARTHRITIS AND CARTILAGE, 2013, 21 : S167 - S167
  • [48] Intrathecal Therapy for Cancer and Non-Cancer Pain
    Hayek, Salim M.
    Deer, Timothy R.
    Pope, Jason E.
    Panchal, Sunil J.
    Patel, Vikram
    PAIN PHYSICIAN, 2011, 14 (03) : 219 - 248
  • [49] Chronic non-cancer pain and opioid dependence
    Littlejohn, C
    Baldacchino, A
    Bannister, J
    JOURNAL OF THE ROYAL SOCIETY OF MEDICINE, 2004, 97 (02) : 62 - 65
  • [50] The burden of opioid-induced constipation among patients with cancer pain and patients with non-cancer pain
    LoCasale, R.
    King, F.
    Margolis, M. K.
    Coyne, K.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S229 - S230